脊髓性肌萎缩症临床试验招募信息（全球在招）
这里汇总了全球正在招募患者的 脊髓性肌萎缩症（国际通用名 spinal muscular atrophy）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖SMA等说法。
正在招募的脊髓性肌萎缩症新药试验
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
不适用招募中IrelandNCT05663008Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy
不适用招募中法国NCT06321965Long Read Analysis in Spinal Muscular Atrophy - LOREASI
不适用招募中法国NCT07332702A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
III 期招募中美国澳大利亚Brazil中国NCT07221669Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
II 期 / III 期招募中日本NCT06862596A Registry Based Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents With Spinal Muscular Atrophy
不适用招募中加拿大NCT06396325A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
III 期招募中美国NCT07444476A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)
不适用招募中EgyptNCT07531719Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
I 期 / II 期招募中中国NCT05824169Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
不适用招募中美国NCT06839469Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
不适用招募中BelgiumNCT07136844Neonatal Spinal Muscular Atrophy (SMA) Screening
不适用招募中中国台湾NCT03217578
脊髓性肌萎缩症试验不在中国大陆，还能参加吗？
可以尝试四条现实路径：查找国内同类试验、申请同情用药与扩展准入、赴境外研究中心入组、直接写信给申办方申请在华开展。本站提供中英文对照的咨询信模板，患者和家属填写基本情况即可生成。